Ireland-based drug developer Elan has spun out its research and development unit but will retain a 14% to 18% stake.
Elan will fund the drug discovery unit, Neotope Biosciences, and will provide $130m, which is about two years’ worth of funding for its research, according to news provider Fierce Biotech.
Dale Schenk is chief executive of Neotope.